(Q53315058)

1 July 2019

title

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. (English)

1 reference

1 July 2019

author

Chitra Hosing

21

1 reference

PubMed publication ID

26472485

13 May 2018

http://europepmc.org/abstract/MED/26472485

Elizabeth J Shpall

19

Elizabeth J Shpall

1 reference

1 July 2019

Uday R Popat

5

Uday Popat

1 reference

1 July 2019

Richard E Champlin

16

Richard E Champlin

1 reference

1 July 2019

Gabriela Rondon

13

Gabriela Rondon

1 reference

1 July 2019

Amanda L Olson

10

Amanda Olson

1 reference

1 July 2019

Stefan O Ciurea

15

Stefan Ciurea

1 reference

1 July 2019

Amin M Alousi

14

Amin Alousi

1 reference

1 July 2019

Betul Oran

4

Betul Oran

1 reference

1 July 2019

Simrit Parmar

8

Simrit Parmar

1 reference

1 July 2019

Partow Kebriaei

11

Partow Kebriaei

1 reference

1 July 2019

Muzaffar Qazilbash

6

Muzaffar Qazilbash

1 reference

1 July 2019

Katayoun Rezvani

9

Katayoun Rezvani

1 reference

1 July 2019

Nina Shah

7

Nina Shah

1 reference

1 July 2019

author name string

Philip A Thompson

1

1 reference

1 July 2019

Travis Perera

2

1 reference

1 July 2019

David Marin

3

1 reference

1 July 2019

Paolo Anderlini

12

1 reference

1 July 2019

Ashish Bajel

17

1 reference

1 July 2019

Jeffrey Szer

18

1 reference

1 July 2019

David Ritchie

20

1 reference

1 July 2019

publication date

23 December 2015

1 reference

1 July 2019

published in

Leukemia & Lymphoma

1 reference

1 July 2019

volume

57

1 reference

1 July 2019

issue

7

1 reference

1 July 2019

page(s)

1607-1615

1 reference

1 July 2019

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Umbilical cord blood transplantation: the first 25 years and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1105370

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

21 January 2018

1 reference

12 December 2020

Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?

1 reference

12 December 2020

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

1 reference

12 December 2020

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula

1 reference

12 December 2020

Pursuing the goal of a donor for everyone in need

1 reference

12 December 2020

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

1 reference

12 December 2020

Report of the Committee on Hodgkin's Disease Staging Classification

1 reference

12 December 2020

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

12 December 2020

High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.

1 reference

12 December 2020

Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease

1 reference

12 December 2020

10.3109/10428194.2015.1105370

Identifiers

DOI

1 reference

1 July 2019

PMC publication ID

6545894

1 reference

1 July 2019

PubMed publication ID

26472485

1 reference

1 July 2019